Urogen Pharma (NASDAQ:URGN) Given Average Rating of "Buy" by Brokerages

Key Points

• Urogen Pharma has received a consensus rating of "Buy" from nine analysts, with one holding a strong buy rating and seven assigning buy ratings, while the average twelve-month price target is $32.00.
• Insider transactions showed significant sales; Mark Schoenberg sold 10,000 shares at an average price of $17.69, reducing his stake by 6.32%.
• Urogen Pharma's stock performance reveals a one-year low of $3.42 and a high of $21.01, while the company posted a quarterly EPS of ($1.05), missing estimates.

Shares of Urogen Pharma (NASDAQ:URGN - Get Free Report) have been assigned an average recommendation of "Buy" from the nine research firms that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold recommendation, seven have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $32.00.

A number of brokerages have recently commented on URGN. Oppenheimer set a $31.00 price target on Urogen Pharma and gave the company a "buy" rating in a report on Friday, June 13th. Scotiabank restated an "outperform" rating on shares of Urogen Pharma in a research note on Friday, June 13th. Piper Sandler began coverage on Urogen Pharma in a research report on Monday, August 18th. They set an "overweight" rating and a $36.00 price target for the company. The Goldman Sachs Group set a $16.00 price objective on shares of Urogen Pharma and gave the company a "neutral" rating in a report on Friday, June 13th. Finally, HC Wainwright cut their price objective on shares of Urogen Pharma from $50.00 to $40.00 and set a "buy" rating on the stock in a research report on Monday, August 11th.

Urogen Pharma Price Performance

Shares of Urogen Pharma stock traded up $0.14 on Friday, hitting $19.25. The company had a trading volume of 895,349 shares, compared to its average volume of 1,078,619. The stock has a 50-day moving average of $18.09 and a 200-day moving average of $12.79. Urogen Pharma has a twelve month low of $3.42 and a twelve month high of $21.71. The firm has a market capitalization of $890.51 million, a P/E ratio of -5.80 and a beta of 1.10.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($1.05) EPS for the quarter, missing analysts' consensus estimates of ($0.82) by ($0.23). The company had revenue of $24.22 million for the quarter, compared to analyst estimates of $23.06 million. Urogen Pharma had a negative return on equity of 97,487.15% and a negative net margin of 164.44%. Equities analysts predict that Urogen Pharma will post -3.12 EPS for the current year.

Insider Activity

In other news, insider Mark Schoenberg sold 10,000 shares of the stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $17.69, for a total transaction of $176,900.00. Following the completion of the transaction, the insider directly owned 148,229 shares in the company, valued at $2,622,171.01. This represents a 6.32% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, General Counsel Jason Drew Smith sold 1,520 shares of the firm's stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $19.11, for a total value of $29,047.20. Following the completion of the transaction, the general counsel owned 43,305 shares of the company's stock, valued at $827,558.55. The trade was a 3.39% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 25,062 shares of company stock worth $465,115 over the last three months. Insiders own 4.70% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in URGN. China Universal Asset Management Co. Ltd. lifted its holdings in Urogen Pharma by 9.4% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 9,261 shares of the company's stock valued at $127,000 after purchasing an additional 797 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Urogen Pharma by 4.7% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,667 shares of the company's stock valued at $231,000 after purchasing an additional 969 shares during the period. Wellington Management Group LLP raised its position in shares of Urogen Pharma by 0.8% in the first quarter. Wellington Management Group LLP now owns 148,078 shares of the company's stock valued at $1,638,000 after purchasing an additional 1,125 shares during the period. Main Street Financial Solutions LLC lifted its stake in shares of Urogen Pharma by 8.2% during the 2nd quarter. Main Street Financial Solutions LLC now owns 25,968 shares of the company's stock worth $356,000 after buying an additional 1,968 shares during the last quarter. Finally, Rhumbline Advisers boosted its holdings in shares of Urogen Pharma by 4.3% during the 1st quarter. Rhumbline Advisers now owns 53,466 shares of the company's stock worth $591,000 after buying an additional 2,196 shares during the period. Institutional investors and hedge funds own 91.29% of the company's stock.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.